Chiesi registers Phase 3 trial of CHF5993 vs Seretide in adolescent asthma
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 700 participants and start on November 16, 2026. It compares CHF5993 100/6/12.5 μg pMDI to Seretide Evohaler 125/25 μg pMDI over 52 weeks in adolescents with uncontrolled asthma.
Primary source
ClinicalTrials.gov registry record, October 5, 2026
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma
Read the source: Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation